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Summary Complicated skin and skin structure infections encompass a diverse range
of diseases frequently caused by Gram-positive pathogens, and most commonly by
Staphylococcus aureus and Streptococcus pyogenes. Treatment of these infections
represents a growing clinical challenge as increases in multi-drug-resistant organisms and
cross-resistance to antimicrobial therapy have made empiric therapeutic choices more
difﬁcult, particularly for patients with known risk factors or who are immunocompromised.
Complicating this issue has been the relative lack of new agents with antimicrobial potency
against prevalent resistant species such as meticillin-resistant S. aureus (MRSA).
Tigecycline, a novel glycylcycline, is a broad-spectrum antibiotic with potent microbi-
ological activity against the wide variety of organisms implicated in the aetiology of
complicated skin and skin structure infections. Recent phase III clinical data conﬁrm
previous observations on the safety and efﬁcacy of tigecycline for the treatment of
complicated skin and skin structure infections.
Tigecycline was shown to be non-inferior to combination vancomycin–aztreonam regimens
and exhibited high clinical success rates. MIC90 values for tigecycline were uniformly low for
both susceptible and resistant pathogens. Adverse events were similar in incidence for both
patient populations, with nausea and vomiting reported more frequently with tigecycline-
treated patients while rash and elevated liver transaminases were most commonly observed
in the vancomycin–aztreonam treatment group.
Tigecycline helps to address the urgent need for new antimicrobial agents to
combat the emergence of multi-drug-resistant Gram-positive pathogens. Current clinical,
microbiological and safety data support the use of tigecycline as a valuable therapeutic
option in the treatment of complicated skin and skin structure infections.
© 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.
Introduction
Complicated skin and skin structure infections (cSSSI)
describe a variety of conditions including post-surgical
or traumatic wound infections, severe carbunculosis,
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erysipelas, cellulitis with drainage, cutaneous abscess and
diabetic or ischemic foot infections. By deﬁnition, these
infections often require surgical intervention since the
infectious process has likely spread to deeper soft tissue,
i.e., fascia and muscle layers.
Complicated SSSI is a painful and disruptive condition
that not only places a signiﬁcant burden on healthcare
resources but is also responsible for employee absenteeism
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and lost work time. Each year, an estimated two
million people suffer from skin infection in France,
Germany, Italy, Spain and the United Kingdom alone.
In 1995 an estimated 330,000 patients in the USA and
4300 patients in Scotland required hospital treatment
for SSSIs, representing approximately 0.1% of the adult
population 1,2.
Empiric antimicrobial treatment of cSSSIs remains
challenging due to a diverse bacterial aetiology that
includes Gram-positive organisms, enteric Gram-negative
bacilli, Pseudomonas aeruginosa and anaerobes. Gram-
positive organisms, frequently Staphylococcus aureus and
Streptococcus pyogenes, are the principal causative agents
of SSSI. Surgical site infections have a reported incidence
of 2.6%, accounting for 38% of nosocomial infections in
surgical patients 3. Approximately half of these infections
are caused by S. aureus, enterococci and coagulase-
negative staphylococci 4. Additionally, more than 20% of
patients with chemotherapy-induced neutropaenia develop
SSSIs often from haematogenous dissemination from
sinuses, lungs and the alimentary tract 5.
Recent surveillance initiatives would suggest that
meticillin-resistant Staphylococcus aureus has become
a signiﬁcant pathogen for many nosocomial infections
including cSSSIs. A recent pathogen prevalence review
from France, Germany and Italy showed the three
most commonly isolated pathogens with cSSSI in their
patients with cSSSI to be S. aureus, P. aeruginosa and
Escherichia coli 6. Factors known to predispose patients
for MRSA infection include diabetes, invasive procedures,
chronic wounds, previous antibiotic use or previous MRSA
colonization and lengthy stay in hospital or long-term care
facility 7,8.
As stated, the diabetic group of patients are at particular
risk for infection due to MRSA. This relates to the chronicity
of lower limb ulceration, recurrent hospitalization,
recurrent surgical intervention and repetitive exposure
to courses of antibiotics. Foot infection is the number 1
reason for diabetics to be hospitalised and annually more
than 1 million diabetic patients suffer amputation of a leg,
more commonly due to sepsis secondary to neuropathic
ulceration than to ischaemia. Initial therapy in these
patients should be empiric and based on severity of
infection. Serious or extensive infections should be treated
with antimicrobial agents with activity against Gram-
positive cocci (including MRSA), Gram-negative bacilli and
anaerobic organisms 9.
As MRSA infections have increased, the utility of tradi-
tional therapies such as antistaphylococcal penicillins or
cephalosporins has been dramatically compromised, leav-
ing glycopeptide antibiotics (vancomycin or teicoplanin)
as the principal clinical option. However, increasing
concern about the generation of vancomycin resistance
among enterococci and staphylococci has spurred interest
in alternate therapies for the management of many
nosocomial diseases.
Tigecycline, a novel glycylcycline, has been recently
approved for the treatment of cSSSIs caused by E. coli,
Enterococcus faecalis (vancomycin-susceptible isolates),
meticillin-susceptible S. aureus (MSSA), MRSA, Strep-
tococcus agalactiae, Str. anginosus, Str. intermedius,
Str. constellatus, Str. pyogenes and Bacteroides fragilis.
Tigecycline has a broad spectrum of activity which
is unaffected by the presence of commonly occurring
tetracycline-resistance mechanisms, extended-spectrum
b-lactamases, penicillin-binding protein mutations or
gyrase mutations.
Current results from a phase III clinical program have
conﬁrmed the safety and efﬁcacy of tigecycline for
the treatment of cSSSI against a wide range of Gram-
positive, Gram-negative and anaerobic pathogens including
resistant strains 10. This review provides an overview
on currently recommended therapy and the challenges
faced by clinicians in the treatment of cSSSI, along
with the potential therapeutic beneﬁts and advantages of
tigecycline therapy applied to this patient population.
Methods
A literature review and MEDLINE search found surveil-
lance, randomised controlled trials, outcome studies
and expert consensus opinion. Relevant articles were
retrieved using MeSH terms “complicated skin and skin
structure infections”, “skin and soft tissue infections”,
“Gram-positive pathogens”, “Staphylococcus aureus”,
“methicillin-resistant Staphylococcus aureus”, “MRSA” and
“nosocomial infections”. Recently published guidelines on
other aspects of nosocomial sepsis, such as nosocomial
pneumonia, where resistant pathogens, e.g. MRSA, are also
emerging, were also reviewed. In addition, abstracts from
the Interscience Conference on Antimicrobial Agents and
Chemotherapy (ICAAC); the European Congress of Clinical
Microbiology and Infectious Diseases (ECCMID) and the
International Congress on Infectious Diseases (ICID) were
also reviewed.
Results
3.1. Microbiology of cSSSI
Skin and skin structure infections are caused by a
wide number of organisms including Pseudomonas, Gram-
negative bacilli and anaerobes, but the predominant
causative pathogens remain Gram-positive species. Recent
surveillance data identiﬁed S. aureus as the princi-
pal causative organism in over 40% of documented
infections 11. The incidence of other key pathogens
was noted as follows: Pseudomonas aeruginosa (12%),
Escherichia coli (10%), Enterococcus spp. (8%), Klebsiella
spp. (6%) and Enterobacter spp. (6%).
Impetigo, cellulitis and erysipelas are often the result
of infection with S. aureus and/or Str. pyogenes. Clinical
presentation is often important in differentiating the
causative pathogen. Necrotising infections that are mo-
nomicrobial are caused by Str. pyogenes, Vibrio vulniﬁcus
or Aeromonas hydrophila. Recently, necrotising fasciitis
was reported in a patient with MRSA infection 12. While
surgical intervention is the primary option, antimicrobial
coverage for polymicrobial necrotising fasciitis must be
effective against such diverse pathogens as E. coli,
Peptostreptococcus spp., group B, C or G streptococci,
S. aureus and anaerobes.
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Surgical site infections are a common occurrence
with a reported incidence from the National Nosocomial
Infection Surveillance System of 2.6%, representing 38% of
nosocomial infections in hospitalised patients 13. For
surgical procedures that do not enter the intestinal or
genital tracts, the predominant causative organisms are
S. aureus, including MRSA, and streptococcal species.
Operations involving the intestinal tract or female genital
tract have a high likelihood of infection by both facultative
and aerobic Gram-positive and Gram-negative pathogens.
Infections in immunocompromised patients are caused
by both Gram-negative and Gram-positive organisms.
Principal Gram-negatives include E. coli, Klebsiella species
and P. aeruginosa; however, recent data would suggest
that the relative incidence of Gram-negatives is decreas-
ing due to increased ﬂuoroquinolone or trimethoprim–
sulfamethoxazole prophylaxis 14. Increased used of in-
dwelling vascular access devices has, in contrast, resulted
in more frequent isolation of Gram-positive organisms such
as coagulase-negative staphylococci, viridans streptococci,
enterococci and S. aureus.
3.2. Currently recommended empiric therapy
Recommendations of empiric and targeted therapies for
skin and skin structure infections have recently been
published 15,16. Mild to moderately severe soft tissue
infections can be readily managed by a variety of
agents. However, patients displaying signs and symptoms
of systemic toxicity (e.g., fever, hypothermia, tachycardia,
hypotension, etc.) need rigorous microbiological, chem-
istry and haematologic assessments to assist in the choice
of antimicrobial agent. As both S. aureus and Str. pyogenes
are commonly encountered skin pathogens, empiric
antimicrobial therapy should include agents with activity
against MRSA and macrolide-resistant Str. pyogenes.
Impetigo unresponsive to topical agents, e.g., mupirocin,
is best treated with oral agents effective against S. aureus
and Str. pyogenes. Cloxacillin, cephalexin, clindamycin
and amoxicillin/clavulanate are commonly used therapies.
Erysipelas is frequently caused by group A b-haemolytic
streptococci, to a lesser extent by group C or group G
streptococci, and rarely by group B streptococci or S. au-
reus. Penicillin is the agent of choice, but if staphylococcal
infection is suspected, therapeutic coverage of MRSA is
warranted.
Necrotising infections such as necrotising fasciitis may
be caused by a single pathogen, e.g., Str. pyogenes,
Vibrio vulniﬁcus or Aeromonas hydrophila or may be
polymicrobial in surgical patients or patients with periph-
eral vascular disease, diabetes mellitus, decubitus ulcers
and spontaneous mucosal tears of the gastrointestinal or
genitourinary tract. For severe group A streptococcal and
clostridial necrotising infections, parenteral clindamycin
and penicillin therapy remains the treatment of choice.
Alternate therapy includes vancomycin, teicoplanin, dap-
tomycin, linezolid, or quinupristin/dalfopristin.
For suspected S. aureus infection, nafcillin, cloxacillin,
amoxicillin/clavulanate or cefazolin remain as ﬁrst line
therapy. However, if MRSA is suspected, vancomycin, te-
icoplanin, daptomycin, linezolid, quinupristin/dalfopristin
or tigecycline must be considered. Mixed infections caused
by anaerobes and aerobic Gram-positive or Gram-negative
species may be treated intravenously by a variety of agents
including ampicillin/sulbactam, amoxicillin/clavulanate
or piperacillin/tazobactam plus clindamycin. Alternative
therapies include a ﬂuoroquinolone (ciproﬂoxacin or
levoﬂoxacin) or second/third-generation cephalosporin
(cefuroxime, cefotaxime or ceftriaxone) plus metronida-
zole or clindamycin, or a carbapenem 17,18.
The choice of empiric antimicrobials for surgical site
infections is profoundly affected by whether or not the
surgical procedure entered the intestinal or genital tracts.
Involvement of colonic, vaginal, or upper respiratory
mucosa may induce infections caused by a combination
of aerobic and anaerobic bacteria. Agents of choice for
infections not involving the axilla or perineum include
cloxacillin, ﬁrst-generation cephalosporins, amoxicillin/
clavulanate or ampicillin/sulbactam. Infections arising
from intestinal or genital tract surgery may be treated
by agents such as cefoxitin, ceftizoxime, b-lactam/
b-lactamase inhibitor combinations or carbapenems. Al-
ternative therapy includes a ﬂuoroquinolone or amino-
glycoside plus clindamycin or metronidazole 17,18.
Skin and soft tissue infections in immunocompro-
mised hosts are often hospital-acquired and caused by
drug-resistant pathogens. Current antimicrobial guide-
lines for this patient population have been pub-
lished and empiric therapy with agents such as anti-
pseudomonal cephalosporins (ceftazidime, cefepime),
piperacillin/tazobactam or carbapenems are often ef-
fective alone. Evidence has not shown dual antibiotic
therapy against resistant Gram-negative sepsis, includ-
ing Pseudomonas aeruginosa infection, to be superior
to monotherapy 17,18. However, many authors still ad-
vocate combination of an appropriate b-lactam an-
tibiotic (extended-spectrum penicillin, anti-pseudomonal
cephalosporin or carbapenem) with a synergistic second
antibiotic, usually an aminoglycoside or ﬂuoroquinolone,
and this has been shown to be effective 19,20. Should a
ﬂuoroquinolone be used, only ciproﬂoxacin or levoﬂoxacin
is appropriate, as the newer ﬂuoroquinolones (such as
moxiﬂoxacin, gatiﬂoxacin and gemiﬂoxacin) have inferior
anti-pseudomonal activity. In this group of patients
though, serious consideration should also be given to
combination with an agent which has coverage against
problematic Gram-positive pathogens such as MRSA,
viridans streptococci, vancomycin-resistant enterococci
and penicillin-resistant pneumococci. Tigecycline should
deﬁnitely be considered in this context, as it covers all
these Gram-positive pathogens, as well as most of the
usual Gram-negative pathogens, with the exception of
Pseudomonas aeruginosa.
Several authors and consensus guidelines advocate the
judicious use of glycopeptides and carbapenems in all
empiric regimens, including those for the treatment of
cSSTI 17,18,21-24. Excessive prescription of glycopeptides
contributes to the incidence of vancomycin-resistant
enterococci (VRE) and is implicated in the emergence of
glycopeptide-intermediate sensitive S. aureus. The routine
usage of carbapenems selects for multi-drug-resistant
(MDR) Gram-negative bacilli, e.g. MDR Pseudomonas
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aeruginosa, Stenotrophomonas maltophilia, Burkholderia
cepacia, Morganella morganii and carbapenem-resistant
Acinetobacter baumannii (CRAB). Carbapenem resistance
is usually mediated by an MDR efﬂux pump with associated
porin change, or by the induction of zinc metallo-
enzyme b-lactamases (carbapenemases). Glycopeptide and
carbapenem resistance is exacerbated by a reluctance to
de-escalate therapy when subsequent cultures show these
agents to be inappropriate 25-34.
Concern also exists as to the general over-usage of
ﬂuoroquinolones and third-generation cephalosporins over
the past decade. This has resulted not only in a marked
increase in resistance to these classes of antimicrobial
agents, but also the induction of resistance to other
classes as well. This phenomenon has been termed
‘collateral damage’ 35. Third-generation cephalosporins
induce extended-spectrum b-lactamase (ESBL) resistance,
which is plasmid mediated. The plasmids involved may
confer resistance to other antibiotic classes at the
same time. Fluoroquinolones have been shown in certain
circumstances to induce MDR efﬂux pumps, which are able
to expel numerous antibiotics from most classes, including
carbapenems, which is extremely concerning.
3.3. Clinical challenges to current therapy
Emerging antibiotic resistance among S. aureus is a
signiﬁcant concern. In a recent North American surveillance
initiative, approximately 30% of S. aureus pathogens
isolated from skin and soft tissue infections were MRSA 36.
The prevalence of MRSA among other countries is also
increasing, with reported rates of 70% in Japan, 45% in
the United Kingdom, 40% in Italy and Greece and 30–50%
in the USA 37-39. Growing macrolide resistance among
Streptococcus pyogenes, a common SSSI pathogen, is also
problematic 40.
Immunocompromised patients, particularly those with
neutropaenia, genetically acquired immunodeﬁciency and
drug-related immunosuppression, are at signiﬁcant risk
of nosocomial infection due to insufﬁcient circulating
neutrophils, lack of adequate myeloid marrow reserve or
congenital or acquired defects in neutrophil function 41,42.
More than 20% of patients with chemotherapy-induced
neutropaenia develop skin and soft-tissue infections most
often from haematogenous dissemination from sites such
as the sinuses, lungs and alimentary tract 5.
Empiric antimicrobial therapy must take into considera-
tion the increased incidence of more virulent pathogens
including those likely to be resistant to conventional
therapies. Tigecycline’s proven in vitro potency against
MRSA, glycopeptide-intermediate S. aureus, penicillin-
resistant S. pneumoniae, vancomycin-resistant enterococci
and ESBL-producing E. coli and K. pneumoniae should af-
ford its consideration as an alternate to vancomycin for the
treatment of patients with proven or suspected resistance
genotypes 43-45. Further, tigecycline has demonstrated
in vitro potency against organisms expressing tetracycline
resistance determinants via ribosomal protection, e.g.
tet(M), or efﬂux, e.g. tet(K).
For documented or suspected infection with an ESBL-
producing Gram-negative bacillus, therapy of choice would
be tigecycline or a class-I carbapenem (ertapenem) 17,28.
For documented or suspected Pseudomonas aerugi-
nosa infection, neither of these agents should be
used, but a class-II carbapenem (imipenem/cilastatin or
meropenem) 17,29. Although traditionally these infections
are treated with dual antibiotic regimens due to fears
relating to virulence, trials have not shown a proven
beneﬁt above monotherapy. Tigecycline is also active
in vitro against most carbapenem-resistant Gram-negative
pathogens, such as carbapenem-resistant Acinetobacter
baumannii. Tigecycline has no activity against MDR
Pseudomonas aeruginosa.
Staphylococcus aureus strains carrying the mecA gene
not only display resistance to meticillin but are often multi-
drug resistant 46,47. Although regional incidence of MRSA
varies widely, current European data suggest the incidence
of MRSA from blood isolates ranges between 20% and 35% 48.
These ﬁndings were supported by a recent British Society
for Antimicrobial Chemotherapy study in which 42% of all
blood isolates tested were MRSA 49. Focusing speciﬁcally
on skin and skin-infection isolates, MRSA occurrences of
28.4% in Latin America and 29.5% in the USA and Canada
have been reported 36,50.
Recently, the incidence of mecA and several common
tetracycline resistance determinants among S. aureus
strains isolated during phase III trials of tigecycline for
skin and skin structure infections has been investigated 51.
Of 503 unique isolates, the mecA gene was present in
120 strains (23.9%) with oxacillin MICs 4mg/mL. Among
MRSA strains, 11.9% of Eastern European isolates and
46.2% of North American isolates expressed tet(M) or tet(K)
tetracycline resistance determinants. While also present in
meticillin-susceptible strains of S. aureus, the incidence
of tetracycline resistance determinants was 3–5-fold lower
than observed with MRSA. Overall, the results of this
study demonstrated that tigecycline potency against MRSA
encoding tet(M) or tet(K) was identical to that against
tetracycline-susceptible strains, a ﬁnding consistent with
the ability of glycylcyclines to retain activity against
both ribosomal protection and efﬂux-mediated tetracycline
resistance.
3.4. Clinical evidence supporting tigecycline therapy in
cSSSI
The results of tigecycline clinical trials in cSSSI are
summarized in Table 1. Data from phase II/III clinical
trials have been reported in which the efﬁcacy and safety
of tigecycline were studied in hospitalised patients with
complicated skin and skin structure infections 52,53. In a
phase II study, two doses of tigecycline (25mg with a
loading dose of 50mg and 50mg with a loading dose of
100mg) were administered intravenously every 12 hours for
7 to 14 days. A total of 164 patients were enrolled, yielding
an intent-to-treat population of 160 of whom 79 were in
the 25mg treatment arm and 81 in the 50mg treatment
arm. The principal diagnoses were infected ulcer (35%) and
major abscess (31%).
At the test-of-cure visit (7–21 days post-treatment)
67% of the 25mg group and 74% of the 50mg group
were rated as cured. Among microbiologically evaluable
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Table 2
Demographic and baseline characteristics of mITT population from phase III study comparing tigecycline to
combination vancomycin plus aztreonam therapy 10
Characteristic Tigecycline (n = 274) Vancomycin/aztreonam (n = 269)
Age, yr [mean (SD)] 48.8 (17.0) 50.1 (17.8)
Gender, no. (%) of patients
Male 167 (60.9) 163 (60.6)
Female 107 (39.1) 106 (39.4)
Ethnic origin, no. (%) of patients
White 227 (82.8) 223 (82.9)
Black 20 (7.3) 20 (7.4)
Asian 19 (6.9) 22 (8.2)
Other 8 (2.9) 4 (1.5)
Weight, kg [mean (SD)] 82.5 (21.0) 81.5 (20.5)
Creatinine clearance, ml/min [mean (SD)] 109.4 (42.4) 104.3 (41.2)
Chief clinical diagnosis, no. (%) of patients
Infected ulcers 25 (9.1) 19 (7.1)
Major abscesses 73 (26.6) 84 (31.2)
Burns 9 (3.3) 8 (3.0)
Deep soft tissue infection 167 (60.9) 157 (58.4)
Cellulitis 160 (58.4) 148 (55.0)
Complicated underlying disease 26 (9.5) 26 (9.7)
10 cm (where anatomically applicable) 144 (52.6) 130 (48.3)
Requiring surgery or drainage 71 (25.9) 73 (27.1)
Wound infection 7 (2.6) 9 (3.3)
Other 0 1 (0.4)
Cause of infection, no. (%) of patients
Trauma 80 (29.2) 81 (30.1)
Spontaneous 144 (52.6) 132 (49.1)
Bite 6 (2.2) 15 (5.6)
Surgery 33 (12.0) 32 (11.9)
Injection 10 (3.6) 9 (3.3)
Other 1 (0.4) 0
Comorbidity conditions, no. (%) of patients
Diabetes mellitus 41 (15.0) 32 (11.9)
Peripheral vascular disease 21 (7.7) 19 (7.1)
patients (45 and 46 patients in the 25mg and 50mg
arms, respectively) end-of-treatment eradication rates
were 62% in the 25mg group and 74% in the 50mg group.
In vitro susceptibility tests of baseline infecting pathogens
including MRSA, MSSA, Str. pyogenes, E. coli, Ent. faecalis
and Ent. faecium yielded MIC90 values for both doses
ranging from 0.06 to 0.5mg/mL.
In the microbiologically evaluable patients, eradication
rates for MRSA (2/4, 50% and 1/4, 25%), MSSA (13/19, 68%
and 14/20, 70%) Str. pyogenes (1/3, 33% and 5/7, 71%),
E. coli (3/5, 60% and 3/3, 100%), Ent. faecalis (4/6, 67%
and 3/3, 100%) and Ent. faecium (1/1, 100% and NA) were
observed for the 25mg and 50mg doses of tigecycline,
respectively. Tigecycline had an acceptable safety proﬁle,
with the most frequent treatment-associated adverse
events being nausea, vomiting and diarrhoea.
A recent phase III clinical trial compared the safety
and efﬁcacy of tigecycline to combination therapy of
vancomycin plus aztreonam 10. A total of 546 patients were
randomised to receive tigecycline 100mg/day (a 100-mg
initial dose followed by 50mg intravenously twice daily)
or the intravenous combination of vancomycin 1 g twice
daily plus aztreonam 2 g twice daily. The principal clinical
diagnoses for all patients were major abscess (28.9%),
cellulitis (56.7%) and infected ulcer (8.1%). Table 2 provides
the complete demographic and baseline characteristics of
the 533 patients in the modiﬁed intent-to-treat population.
Both treatment groups were well matched in terms of
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Table 3
Treatment-emergent adverse events that occurred in 3% of patients 10
Body system and adverse
event
Tigecycline (n = 274)
No. of pts (%)
V/A (n = 269)
No. of pts (%)
Any adverse event 143 (52.2) 118 (43.9)
Body as a whole 46 (16.8) 39 (14.5)
Headache 13 (4.7) 11 (4.1)
Cardiovascular system 16 (5.8) 26 (9.7)
Hypertension 7 (2.6) 14 (5.2)
Digestive system* 89 (32.5) 38 (14.1)
Diarrhea 11 (4.0) 4 (1.5)
Nausea* 69 (25.2) 14 (5.2)
Vomiting* 33 (12.0) 6 (2.2)
Haemic and lymphatic system 18 (6.6) 14 (5.2)
Anaemia 4 (1.5) 9 (3.3)
Metabolic and nutritional 34 (12.4) 30 (11.2)
AST level increased* 4 (1.5) 14 (5.2)
ALT level increased* 5 (1.8) 18 (6.7)
Skin and appendages* 20 (7.3) 37 (13.8)
Pruritis 11 (4.0) 10 (3.7)
Rash 3 (1.1) 10 (3.7)
*Signiﬁcant between-group difference (P < 0.05).
clinical diagnoses, causes of infection and underlying co-
morbidities.
Clinical response at the 12–92 day post-therapy test-of-
cure assessment in both the clinical modiﬁed intent-to-
treat (c-mITT) and clinically evaluable (CE) populations
was the primary end point. Responses for tigecycline
and vancomycin–aztreonam in the c-mITT were 84.3% and
86.9%, respectively, and in the CE population 89.7% versus
94.4%, respectively. Microbiological eradication occurred
in 84.8% of the tigecycline patients compared to 92.3% of
patients receiving combination vancomycin–aztreonam.
In the microbiologically evaluable patients, compara-
tive eradication rates for tigecycline and vancomycin–
aztreonam, respectively, against select pathogens were:
MRSA (5/6, 83.3% and 3/6, 50%), MSSA (54/62, 87.1%
and 55/58, 94.8%) Str. pyogenes (21/22, 95.5% and
16/16, 100%), E. coli (15/16, 93.8% and 13/14, 92.9%),
Ent. faecalis (3/4, 75% and 5/5, 100%), Str. agalactiae
(4/5, 80.0% and 3/3, 100%) and B. fragilis (NA and
1/1, 100%). Tigecycline MIC90s were uniformly low against
susceptible and resistant strains of S. aureus (0.25mg/mL),
Str. pyogenes (0.12mg/mL) and E. coli (0.5mg/mL).
The number of patients with treatment-emergent
adverse events was similar between the two groups and
is summarized in Table 3. Treatment-emergent adverse
events that were statistically different between the two
study regimens included nausea (25.2%) and vomiting (12%)
which occurred more frequently with tigecycline-treated
patients while patients receiving vancomycin–aztreonam
had increased incidence of rash (3.7%) and elevations in
liver transaminases (11.2%).
Discussion
Complicated SSSIs are caused by a diverse variety of
bacterial species. In many instances, ﬁrst-line agents
recommended by current therapeutic guidelines retain
their clinical utility. However, increasing bacterial resis-
tance, particularly among Gram-positive organisms in the
hospital setting, has rendered many traditional agents
ineffective against pathogens such as MRSA or vancomycin-
resistant enterococci. Compounding this problem is the
dearth of novel antimicrobials having sufﬁcient potency
and spectrum of activity to allow for empiric and targeted
treatment of cSSSIs.
Tigecycline is a novel glycylcycline exhibiting a broad
spectrum of activity against Gram-positive, Gram-negative
and anaerobic pathogens, including strains known to
be resistant to other antimicrobial classes. Tigecycline
inhibits protein synthesis via strong ribosomal interaction
and is generally unaffected by efﬂux or ribosomal
protection mechanisms. Additionally, extended-spectrum
b-lactamases, altered penicillin-binding proteins or gyrase
mutations do not affect tigecycline potency.
Recent clinical data have conﬁrmed the efﬁcacy of
tigecycline for the treatment of cSSSIs. In a large
randomised, controlled, double-blind phase III study,
tigecycline was shown to be non-inferior at the test-of-
cure assessment to vancomycin–aztreonam combination
therapy in the primary efﬁcacy outcome groups, i.e., the
clinically evaluable and the clinical modiﬁed intent-to-
treat populations. Microbiological evaluation conﬁrmed the
potency of tigecycline with uniformly observed MIC90 values
of 0.12–0.5mg/mL against all prevalent study isolates
including MRSA. Treatment-emergent adverse events
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were similar between the two treatment groups, with
nausea and vomiting commonly reported for tigecycline
compared to rash and increased aminotransferase levels
for combination vancomycin–aztreonam.
The latest phase III clinical safety and efﬁcacy data
reafﬁrm earlier observations from phase II studies demon-
strating tigecycline’s efﬁcacy in the treatment of cSSSIs.
Further, tigecycline’s potent microbiological activity, which
remains undiminished in the presence of bacteria with
common resistance genotypes, supports empiric use of
this therapeutic for the cost-effective treatment of
various cSSSI indications currently managed by agents with
reduced activity against multi-drug-resistant organisms or
by combination therapy. Given the concerning increase
in resistant pathogens and lack of new antimicrobials for
treatment of challenging diseases, the judicious use of
tigecycline in the treatment of cSSSI appears warranted.
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